- Home
- ATOS vs THTX Comparison
ATOS vs THTX Comparison
Compare ATOS & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- THTX
- Stock Information
- Founded
- ATOS 2009
- THTX 1993
- Country
- ATOS United States
- THTX Canada
- Employees
- ATOS N/A
- THTX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- THTX Health Care
- Exchange
- ATOS Nasdaq
- THTX Nasdaq
- Market Cap
- ATOS 112.5M
- THTX 119.1M
- IPO Year
- ATOS 2012
- THTX N/A
- Fundamental
- Price
- ATOS $0.86
- THTX $2.53
- Analyst Decision
- ATOS Strong Buy
- THTX Hold
- Analyst Count
- ATOS 4
- THTX 1
- Target Price
- ATOS $6.17
- THTX N/A
- AVG Volume (30 Days)
- ATOS 668.8K
- THTX 118.4K
- Earning Date
- ATOS 05-13-2025
- THTX 07-09-2025
- Dividend Yield
- ATOS N/A
- THTX N/A
- EPS Growth
- ATOS N/A
- THTX N/A
- EPS
- ATOS N/A
- THTX N/A
- Revenue
- ATOS N/A
- THTX $88,666,000.00
- Revenue This Year
- ATOS N/A
- THTX N/A
- Revenue Next Year
- ATOS N/A
- THTX $15.13
- P/E Ratio
- ATOS N/A
- THTX N/A
- Revenue Growth
- ATOS N/A
- THTX 13.52
- 52 Week Low
- ATOS $0.55
- THTX $1.12
- 52 Week High
- ATOS $1.66
- THTX $3.13
- Technical
- Relative Strength Index (RSI)
- ATOS 51.39
- THTX 46.39
- Support Level
- ATOS $0.84
- THTX $2.57
- Resistance Level
- ATOS $0.93
- THTX $2.68
- Average True Range (ATR)
- ATOS 0.06
- THTX 0.08
- MACD
- ATOS -0.00
- THTX -0.02
- Stochastic Oscillator
- ATOS 66.40
- THTX 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.